Bionure launches a crowdfunding campaign to fund the preparation the phase 2 study of BN201 Blog Post

Bionure, a biotech company specialized in neuroprotection based in the Barcelona Science Park, has launched a crowdfunding campaign through the Spanish platform of Capital Cell with the objective of raising €1.3M that will be used to finance the preparation of the phase 2 study of its neuroprotectant BN201. The campaign (multiplesmotivos.com) is part of a bridge round of €2.4M that will cover the expenses of regulatory and technical preparation of the phase 2 study.

 

GlyCardial Diagnostics wins the EmprendedorXXI 2019 Award in the ‘Health Tech’ category Blog Post

GlyCardial Diagnostics has won the  the EmprendedorXXI Award in the ‘Health Tech’ category, one of the six awards granted in its twelfth year to recognize those companies in Spain and Portugal with greatest growth potential in several sectors linked to the new innovation trends. The winners have been selected from 961 companies in Spain and Portugal. The biotechnology company, headquartered in the Barcelona Science Park, adds this award to the EmprendedorXXI Award in Catalonia, which it received on 9 May.

 

GlyCardial Diagnostics receives the EmprendedorXXI Award in Catalonia Blog Post

The companies GlyCardial Diagnostics, based in the Barcelona Science Park, and Mitiga Solutions, have been honoured with the EmprendedorXXI Award in Catalonia, which is promoted by CaixaBank –through DayOne, its specialized division that provides banking services for technology and innovation companies and its investors- and awarded jointly by the Ministry of Industry, Commerce and Tourism, through Empresa Nacional de Innovación, S.A. (ENISA). The award ceremony was held yesterday in the Recinte Modernista of the Hospital de Sant Pau as part of the ‘DayOne Innovation Summit’ event. Outside of the regional prize, next May 14th the sectorial EntrepreneurXXI Awards will be awarded to 6 nationwide companies with the highest growth potential in their sector.

 

The Barcelona Science Park launches the 15th edition of BATX2LAB Blog Post

The Barcelona Science Park has just opened the registration for the 15th edition of BATX2LAB, which offers High School students the chance to carry out the practical part of their research project in the PCB laboratories under the tutorship of a scientist. This initiative is part of PCB’s Research in Society programme –a proposal to bring science to citizens and promote research careers in young student– that offers over 100 activities in which around 5,000 people participate every year.

 

Bionure reports successful Phase 1 Study for lead candidate BN201 Blog Post

Bionure, a biotech company specialized in neuroprotection based in the Barcelona Science Park, today announces that it has successfully concluded its Phase 1 clinical study with its lead candidate BN201, a first-in-class compound to treat neurodegenerative diseases such as Multiple Sclerosis (MS). The company is now preparing a Series B funding round to finance the Phase 2 clinical program. 

 

UTOX-PCB takes part in the Preclinonco project to develop innovative new cancer drugs Blog Post

The Unit of Experimental Toxicology and Ecotoxicology of the Barcelona Science Park (PCB) is taking part in a consortium that aims to develop and provide preclinical checks for new candidates for first-in-class cancer drugs. The project, called Preclinonco, has just received an injection of nearly 350,000 euros from the Retos-Colaboración 2017 program, promoted by the Ministry of Science, Innovation and Universities with ERDF funding.

 

The Barcelona Science Park announces a new artistic intervention competition Blog Post

The Barcelona Science Park (PCB) is holding a new artistic intervention competition which offers participants the chance to design, with total freedom, a 125 metre-long space in the Cluster building, one of the main communication channels between the various research laboratories of the PCB. The ‘L’aigua és vida‘ [Water is life] project, by painter Kelly Arrontes, won the previous competition in 2017.

 

SOM Biotech initiates of Phase 2a clinical trial of SOM3355 in Huntington’s disease patients Blog Post

SOM Biotech, a clinical-stage biopharmaceutical company –with headquarters in Barcelona Science Park– that discovers and develops drugs for orphan indications in the central nervous system,  has initiated of Phase 2a clinical trial of its compound SOM3355 for the treatment of the chorea movements associated to Huntington’s disease. The investigational product is a repositioned drug, currently commercialized for the treatment of hypertension. 

 

The call for the 2018-2019 Research in Society program is open Blog Post

Today, Monday 2 July, the Barcelona Science Park (PCB) has kicked off its 18th Research in Society programme with the opening of the pre-registration period for the experimental workshops “Discover research!” and “Do research!”. Places will be allocated to applicant schools in a draw using the list of reservation numbers.